Metagenomi, Inc. share price logo

Metagenomi, Inc.

NASDAQ: MGX

$1.23

+0.03

(+2.50%)

as on

Metagenomi, Inc. Stock Performance

as on August 24, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.20
    $1.26
    downward going graph

    2.44%

    Downside

    2.44%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.13
    $3.95
    downward going graph

    8.13%

    Downside

    221.14%

    Upside

    downward going graph

Metagenomi, Inc. share price movements today

Previous Close
$1.20
Open
$1.20
Volume
1.2M
Market Cap
$46.5M
Day's Low - High
$1.20 - $1.26
52 Week Low - High
$1.13 - $3.95

Metagenomi, Inc. Historical Returns

1 Month Return
-0.81 %
3 Month Return
-6.11 %
1 Year Return
-33.87 %
3 Year Return
0 %
5 Year Return
0 %

Metagenomi, Inc. Stock Fundamentals & Key Indicators

Check Metagenomi, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$46.5M

EPS (TTM)

-2.49

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.49

Industry PE ratio

-1.5966015625

PEG Ratio

0.08244608698827896

EBITDA

-88.5M

Revenue (TTM)

13.6M

Profit Margin

74.29%

Return On Equity TTM

-63.65%

Metagenomi, Inc. Stock Valuation

Track how Metagenomi, Inc. P/E has moved over time to understand its valuation trends.

Metagenomi, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-8.86x)

December 31, 2022

Industry (-1.60x)

December 31, 2025

Today (-0.69x)

December 31, 2025

Highest (-0.69x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.69x

Metagenomi, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Metagenomi, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Metagenomi, Inc. image
Metagenomi, Inc.
BUY$46.5MNA-0.4974.29%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Moderna image
Moderna
BUY$25.3B-84.24%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Metagenomi, Inc. Stock including INR - Dollar returns

The Metagenomi, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Metagenomi, Inc. investment value today

Current value as on today

₹72,244

Returns

-₹27,756

(-27.76%)

Returns from Metagenomi, Inc. Stock

-₹33,871 (-33.87%)

Dollar Impact

₹6,115 (+6.12%)

Analyst Recommendation on Metagenomi, Inc. Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Metagenomi, Inc.. Average target price of $7

Metagenomi, Inc. Share Price Target

Get share price movements and forecasts by analysts on Metagenomi, Inc..

What analysts predicted

82.43%UPSIDE

Target Price

$7

Current Price

$1.23

Analyzed by

3 Analysts

Target

$7.00

Metagenomi, Inc. target price $7, a slight upside of 82.43% compared to current price of $1.23. According to 3 analysts rating.

Indian Investors' Interest in Metagenomi, Inc. Stock

Search interest for Metagenomi, Inc. Stock has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-48% versus previous 30 day period

Metagenomi, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
11
20
11
9
4
8
8
3
1
0
Gross Profit
-20
20
11
9
-21
-13
7
2
0
0
Operating Income
-29
-16
-22
-20
-27
-20
-22
-24
-24
-28
EBITDA
-23
-11
-19
-23
-23
-18
-19
-21
-21
-26
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
1
1
1
1
Income Before Tax
-25
-12
-20
-24
-24
-19
-20
-22
-23
-27
Income Tax Expense
-
-2
-2
-1
0
0
0
0
0
-
Net Income
-25
-10
-18
-23
-25
-19
-20
-22
-23
-27
Net Profit Margin
-181.74%
100.00%
100.00%
100.00%
-509.21%
-164.38%
84.71%
66.76%
30.85%
100.00%

Metagenomi, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
17
44
52
25
Gross Profit
0
15
-49
52
19
Operating Income
-23
-44
-78
-88
-96
EBITDA
-20
-39
-56
-78
-82
Interest Expense
0
0
-
-
-
Depreciation
0
1
4
5
5
Income Before Tax
-21
-41
-60
-83
-87
Income Tax Expense
-
2
8
-5
0
Net Income
-21
-43
-68
-78
-87
Net Profit Margin
-59.26%
89.92%
-110.93%
100.00%
78.91%

Metagenomi, Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-25
-10
-18
-23
-25
-19
-20
-22
-23
-27
Operating Cash Flow
-29
-26
-26
-26
-22
-21
-21
-23
-21
-19
Investing Cash Flow
-94
-13
-8
28
24
19
27
32
3
33
Financing Cash Flow
86
-2
0
-
0
0
0
0
0
0
Change in Cash
-38
-41
-36
2
1
-2
5
8
-16
13

Metagenomi, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-21
-43
-68
-78
-87
Operating Cash Flow
24
29
-91
-109
-88
Investing Cash Flow
-74
-122
45
-88
103
Financing Cash Flow
39
239
1
84
0
Change in Cash
-10
147
-44
-113
14

Mutual Funds that own Metagenomi, Inc. Stock

Check out the Mutual Funds with significant holdings in Metagenomi, Inc..

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
2.80049%
1057944
Bridgeway Funds, Inc.
1.030518%
389300
Fidelity Concord Street Trust
0.68015%
256941
Meeder Funds
0.014548%
5496
ProFunds
0.000238%
90

Global Institutional Holdings in Metagenomi, Inc.

Funds
Holdings
Vanguard
2.8%
iShares
0.25%
Bridgeway
0.1%

Insights on Metagenomi, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 466.0% return, outperforming this stock by 502.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, MGX stock has moved down by -8.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 5 quarters, -19.90M → -27.48M (in $), with an average decrease of 8.6% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 8.65M → -257.0K (in $), with an average decrease of 81.2% per quarter

About Metagenomi, Inc.

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
OrganisationMetagenomi, Inc.
Headquarters5959 Horton Street, EmeryVille, CA, United States, 94608
IndustryBiotechnology
CEODr. Jian Irish M.B.A., Ph.D.
E-voting on sharesClick here to vote

Key Management of Metagenomi, Inc.

Name

Title

Ms. Pamela M. Wapnick M.B.A.

Chief Financial Officer

Mr. Matthew L. Wein J.D.

Gen­er­al Coun­sel, Com­pli­ance Offi­cer, Head of BD&L and Cor­po­rate Secretary

Dr. Joseph Knowles M.D.

Co-Founder & Member of Scientific Advisory Board

Mr. Mark Leonard

Senior Vice Pres­i­dent of Tech­ni­cal Devel­op­ment & Oper­a­tions

Dr. Alan Brooks Ph.D.

Senior Vice President of Research

Ms. Katalin Kauser M.D., Ph.D.

Senior Vice Pres­i­dent of Trans­la­tion­al Biol­o­gy

Dr. Jian Irish M.B.A., Ph.D.

CEO, President & Director

FAQs

What is Metagenomi, Inc. share price today?

Metagenomi, Inc. share price today is $1.23 as on at the close of the market. Metagenomi, Inc. share today touched a day high of $1.26 and a low of $1.20.

What is the 52 week high and 52 week low for Metagenomi, Inc. share?

Metagenomi, Inc. share touched a 52 week high of $3.95 on and a 52 week low of $1.13 on . Metagenomi, Inc. stock price today i.e. is closed at $1.23,which is 68.86% down from its 52 week high and 8.85% up from its 52 week low.

What is Metagenomi, Inc.'s market capitalisation today?

Metagenomi, Inc. market capitalisation is $0.00T as on .

How to invest in Metagenomi, Inc. Stock (MGX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Metagenomi, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Metagenomi, Inc. Shares that will get you 1.2195 shares as per Metagenomi, Inc. share price of $1.23 per share as on August 24, 2026 at 8:45 am IST.

What is the minimum amount required to buy Metagenomi, Inc. Stock (MGX) from India?

Indian investors can start investing in Metagenomi, Inc. (MGX) shares with as little as ₹95.71 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.10 in Metagenomi, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Metagenomi, Inc. share’s latest price of $1.23 as on August 24, 2026 at 8:45 am IST, you will get 8.1301 shares of Metagenomi, Inc.. Learn more about fractional shares .